ATE407948T1 - Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität - Google Patents

Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität

Info

Publication number
ATE407948T1
ATE407948T1 AT98947759T AT98947759T ATE407948T1 AT E407948 T1 ATE407948 T1 AT E407948T1 AT 98947759 T AT98947759 T AT 98947759T AT 98947759 T AT98947759 T AT 98947759T AT E407948 T1 ATE407948 T1 AT E407948T1
Authority
AT
Austria
Prior art keywords
methods
compositions
specific cytotoxicity
inducing tumor
sequences
Prior art date
Application number
AT98947759T
Other languages
English (en)
Inventor
Abraham Hochberg
Suhail Ayesh
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE407948T1 publication Critical patent/ATE407948T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT98947759T 1997-10-03 1998-10-04 Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität ATE407948T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94360897A 1997-10-03 1997-10-03

Publications (1)

Publication Number Publication Date
ATE407948T1 true ATE407948T1 (de) 2008-09-15

Family

ID=25479934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98947759T ATE407948T1 (de) 1997-10-03 1998-10-04 Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität

Country Status (17)

Country Link
US (2) US6087164A (de)
EP (1) EP1019499B1 (de)
JP (3) JP5153031B2 (de)
KR (1) KR100524262B1 (de)
CN (1) CN1229496C (de)
AT (1) ATE407948T1 (de)
AU (1) AU755774B2 (de)
BR (1) BR9812717B1 (de)
CA (1) CA2308124C (de)
CZ (2) CZ294694B6 (de)
DE (1) DE69840001D1 (de)
HU (1) HU228470B1 (de)
IL (1) IL135430A0 (de)
NO (2) NO328470B1 (de)
PL (1) PL339949A1 (de)
RU (1) RU2214280C2 (de)
WO (1) WO1999018195A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006220A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor 2 expression
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2365901A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE19928342A1 (de) * 1999-06-21 2000-12-28 Deutsches Krebsforsch Vektoren zur gentherapeutischen Tumorbehandlung
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20040209263A1 (en) * 2000-12-07 2004-10-21 Clawson Gary A. Selection of catalytic nucleic acids targeted to infectious agents
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
WO2003102186A1 (fr) * 2002-05-31 2003-12-11 Medinet Co., Ltd. Adn induisant l'expression specifique des cellules cancereuses et vecteur d'expression specifique des cellules cancereuses
US20040180844A1 (en) * 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7063947B2 (en) * 2004-04-08 2006-06-20 Promogen, Inc. System for producing synthetic promoters
US7429482B2 (en) * 2005-01-13 2008-09-30 United States Of America As Represented By The Department Of Veterans Affairs Screening tools for discovery of novel anabolic agents
US8067573B2 (en) 2005-07-07 2011-11-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19 and methods of using same
EP1926814B1 (de) 2005-09-22 2010-04-28 Yissum Research Development Company, of The Hebrew University of Jerusalem Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs
EP2111449B1 (de) * 2007-01-16 2012-03-07 Yissum Research Development Company of the Hebrew University of Jerusalem Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
CN101868241A (zh) 2007-09-28 2010-10-20 英特瑞克斯顿股份有限公司 表达生物治疗分子的治疗基因开关构建物和生物反应器以及它们的应用
BRPI0818937B8 (pt) 2007-10-25 2021-05-25 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd constructos contendo múltiplos cassetes de expressão para terapia de câncer
TWI389696B (zh) 2008-07-02 2013-03-21 Otsuka Pharma Co Ltd 人工腎臟前驅物及其製造方法
EP2379720B1 (de) 2009-01-20 2016-08-17 Alona Zilberberg Durch den promoter mir-21 angetriebene gezielte krebstherapie
EA016223B1 (ru) * 2009-10-07 2012-03-30 Учреждение Российской Академии Наук Институт Молекулярной Генетики Ран Способ и генная конструкция для высокоспецифичного ингибирования нежелательного роста клеток
EP3291799A1 (de) * 2015-05-05 2018-03-14 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Kationische nukleinsäurepolymerzusammensetzungen und verfahren zur herstellung und verwendung davon
SG11202010533WA (en) * 2018-04-30 2020-11-27 Amicus Therapeutics Inc Gene therapy constructs and methods of use
CN110714075B (zh) * 2018-07-13 2024-05-03 立森印迹诊断技术(无锡)有限公司 一种用于检测肺肿瘤良恶性程度的分级模型及其应用
CN111206093A (zh) * 2018-11-21 2020-05-29 立森印迹诊断技术(无锡)有限公司 一种用于检测浸润性膀胱癌的标志物及其应用
CN109609505A (zh) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 一种体内筛选的剪切rna的锤头状核酶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699191B1 (fr) * 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IL108879A (en) * 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique

Also Published As

Publication number Publication date
RU2214280C2 (ru) 2003-10-20
US6087164A (en) 2000-07-11
PL339949A1 (en) 2001-01-15
WO1999018195A2 (en) 1999-04-15
AU755774B2 (en) 2002-12-19
IL135430A0 (en) 2001-05-20
CZ294941B6 (cs) 2005-04-13
JP2006304801A (ja) 2006-11-09
EP1019499A2 (de) 2000-07-19
CA2308124C (en) 2008-07-08
CN1229496C (zh) 2005-11-30
AU9457198A (en) 1999-04-27
NO20001684L (no) 2000-06-02
NO331723B1 (no) 2012-03-05
NO328470B1 (no) 2010-02-22
CZ20001201A3 (cs) 2000-09-13
WO1999018195A3 (en) 1999-08-12
JP5153031B2 (ja) 2013-02-27
CZ294694B6 (cs) 2005-02-16
BR9812717A (pt) 2000-08-22
NO20001684D0 (no) 2000-03-31
EP1019499B1 (de) 2008-09-10
JP2008136480A (ja) 2008-06-19
HUP0003745A3 (en) 2002-04-29
KR100524262B1 (ko) 2005-10-28
CA2308124A1 (en) 1999-04-15
KR20010030912A (ko) 2001-04-16
DE69840001D1 (de) 2008-10-23
HUP0003745A2 (hu) 2001-02-28
BR9812717B1 (pt) 2011-06-28
US6306833B1 (en) 2001-10-23
NO20093194L (no) 2000-06-02
HU228470B1 (en) 2013-03-28
CN1280616A (zh) 2001-01-17
JP2001519148A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
ATE407948T1 (de) Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
IL135776A0 (en) Recombinational cloning using nucleic acids having recombination sites
AR110594A2 (es) Construcciones de expresión en plantas y método para expresar una secuencia de adn en plantas
FI972225A0 (fi) Vektorit kudosspesifistä replikaatiota varten
DE69114299D1 (de) Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
WO1999064579A3 (en) Corn oleosin promoter and genes encoding corn desaturases
DE69736432D1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
EP1117672A4 (de) Antisense-modulation der survivin-expression
DE69535704D1 (de) EXPRESSIONSPLASMIDE, DURCH EINEN osmB PROMOTER REGULIERT
IL106894A0 (en) Dorsal tissue affecting factor and compositions
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
AP1968A (en) Recombinant rhabdovirus containing a heterologous fusion protein.
EP1368467A4 (de) Putrescin-n-methyltransferasepromotor
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
EP1070122A4 (de) Induktion apoptischer oder zytotoxischer genexpression durch adenovirus-vermittelten gen-kotransfer
IL126152A0 (en) Recombinant adenoviral vectors for human tumor gene therapy
ZA200202413B (en) Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression.
EP1390388A4 (de) Antisense-modulation der expression des interferon-gamma-rezeptors 1
Tsang et al. Construction of new amplifier expression vectors for high levels of IL-2 gene expression.
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
WO2000078939A3 (de) Vektoren zur gentherapeutischen tumorbehandlung
DE59310334D1 (de) Vektor zur expression von therapeutisch relevanten genen
PL315670A1 (en) Expression of heterological proteins in attenuated bacteria with use of htra promoters

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties